Extended Data Fig. 4: Drug-induced mRNA and protein expression changes.
From: Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics
a) Dose-response curves of mRNA and protein levels of IKZF1. b) Apparent binding affinity constants (pKd = −log10 Kd) of brigatinib-Protein interactions determined by Kinobead competition assays10. CLK1,3,4 are marked by respective text. c) Left panel: Dose-dependent change of mRNA levels (determined by RT-qPCR) for different CLK1-4 domains following treatment with brigatinib. Middle panel: same as left panel but for abemaciclib. Right panel: same as left panel but for milciclib. d) Left panel: dose-response curves of CLK1-4 following treatment with abemaciclib. Middle panel: same as b) but for abemaciclib. Right panel: ratios of the N-terminal and kinase domain transcripts (determined by RT-qPCR) of CLK1-4 in response to abemaciclib. The dotted line marks a 1:1 quantitative ratio of the two mRNAs. e) Same as panel d) but for milciclib.
